Co-Diagnostics (CODX) Expected to Announce Earnings on Tuesday

Co-Diagnostics (NASDAQ:CODX) is projected to post its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect the company to announce earnings of ($3.90) per share and revenue of $0.1260 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:30 PM ET.

Co-Diagnostics Price Performance

Shares of NASDAQ:CODX opened at $2.28 on Tuesday. Co-Diagnostics has a 1 year low of $2.05 and a 1 year high of $46.50. The company has a market cap of $4.78 million, a P/E ratio of -0.08 and a beta of 1.31. The stock’s fifty day moving average price is $2.57 and its 200-day moving average price is $7.76.

Wall Street Analyst Weigh In

CODX has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Co-Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Maxim Group lowered shares of Co-Diagnostics from a “buy” rating to a “hold” rating in a research note on Friday, January 23rd. Finally, HC Wainwright reissued a “neutral” rating on shares of Co-Diagnostics in a report on Monday, November 24th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $55.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Co-Diagnostics by 40.4% in the fourth quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock worth $81,000 after purchasing an additional 129,158 shares during the last quarter. Virtu Financial LLC increased its position in shares of Co-Diagnostics by 393.8% during the 3rd quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock valued at $44,000 after purchasing an additional 100,901 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Co-Diagnostics by 314.1% during the 2nd quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock valued at $47,000 after purchasing an additional 126,105 shares during the last quarter. Institutional investors own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.